Lucitanib for the treatment of HR+/ HER2- metastatic breast cancer: results from the multicohort phase II FINESSE study.

CONCLUSIONS: Lucitanib had modest antitumor activity and significant hypertension-related toxicity in patients with HR+/ HER2- MBC. Although based on small sample sizes, exploratory biomarker analyses suggested patients with high FGFR1 amplification or expression might derive greater benefit. PMID: 31619444 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research